NCT03033225View on ClinicalTrials.gov

Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

September 20, 2023

Study Completion Date

September 20, 2023

Conditions
Advanced Pancreatic CarcinomaLocally Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaPancreatic NeoplasmStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Carcinoma
Interventions
PROCEDURE

Endoscopic Ultrasound

Undergo EUS-guided PDT

PROCEDURE

Fluorescence Imaging

Undergo fluorescence imaging

DRUG

Photodynamic Therapy

Undergo EUS-guided PDT

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Verteporfin

Given IV

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT03033225 - Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study | Biotech Hunter | Biotech Hunter